In two case-controlled studies, increased NPC risk was observed in those patients with a polymorphism in CCND1, which encodes the cell-cycle regulator cyclin D1, as well as TLR3, which encodes a toll-like receptor belonging to the family of pattern recognition receptors involved in innate immunity [23,24]. This evidence concerns the gene TLR3 and nasopharyngeal carcinoma.